Other Events ·
Pulse Biosciences achieves enrollment target of 164 patients in pivotal NANOPULSE-AF clinical study
PLSEPulse Biosciences, Inc.
Pulse Biosciences announced that its NANOPULSE-AF Study has reached the target enrollment of 164 evaluable patients across 15 clinical sites. The prospective, multicenter, non-randomized IDE pivotal investigation evaluates the safety and effectiveness of the nPulse Cardiac Catheter System for treating drug-resistant, symptomatic, paroxysmal atrial fibrillation. Enrollment was completed three months ahead of schedule, with primary endpoints to be assessed at 6 and 12 months post-ablation. Pulse Biosciences is a bioelectric medicine company developing nanosecond pulsed field ablation technology for cardiac arrhythmia treatment.